Patient Agreement for Unlicensed Daratumumab Rapid Rate Infusion Sample Contracts
Patient agreement for unlicensed Daratumumab Rapid Rate InfusionPatient Agreement for Unlicensed Daratumumab Rapid Rate Infusion • April 23rd, 2020
Daratumumab is a drug used to treat multiple myeloma and belongs to a class of drugs known as monoclonal antibodies. It attaches specifically to a protein that is found on the surface of myeloma cells, enabling your immune system to target and kills these cells. Data suggests that a rapid (1.5hours) daratumumab infusion scheduled, in combination with paracetamol, an antihistamine and steroids before each infusion, is well tolerated and safe, when administered from the third infusion onwards. Infusion-related reactions can occur when daratumumab is being given. These include shortness of breath, blocked sinuses, coughing, raised blood pressure and chills and are particularly likely to occur during your first daratumumab infusion. These reactions are often mild, but they can be severe. If you have Chronic obstructive pulmonary disease (COPD), asthma or uncontrolled hypertension, you may be at an increased risk of experiencing daratumumab reaction symptoms. Please let your chemotherapy n